Role of interleukin polymorphisms in gastric cancer: “Pros and cons”

Table 2 Noteworthy gene-variant cancer associations with False-Positive Report Probabilities < 0.2 at a prior probability levels of 0.001 and 0.000001 to detect an OR of 1.5[75]

Gene	Variant	Comparison	FPRF at 0.001 (OR of 1.5)	FPRP at 0.000001 (OR of 1.5)	Cancer
CASP8	Asp302His	GC vs GG	0.028a	0.967	Breast
CHEK2	1100delC	Het vs NC	0.004a	0.782	Breast
TGFB1	Leu10Pro	TT vs CC	0.090a	0.990	Breast
GSTT1	Null	Null vs pres	0.074a	0.988	Colorectal
GSTM1	Null	Null vs pres	< 0.001a	< 0.001a	Bladder
NAT2	Acetylator	S vs I + R	< 0.001a	0.163a	Bladder
MTHFR	C677T	TT vs CT-CC	< 0.001a	0.140a	Stomacha
MDM2	SNP309	GG vs TT	0.162a	0.995	Lung
XPD	Lys751Gln	CC vs AA	0.143a	0.994	Lung
XRCC1	Arg399Gln	AA vs GG	0.038a	0.975	Lung
RNASEL	Asp541Glu	GT + GG vs TT	0.162a	0.995	Prostate
GSTM1	Null	Null vs pres	< 0.001a	< 0.001a	Leukaemia
GSTT1	Null	Null vs pres	0.023a	0.960	Leukaemia

^aThere is a noteworthy association at an FPRP level of 0.2.